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Abstract:  
 
Introduction: Major Depressive Disorder (MDD) is a common debilitating illness worldwide. The vast 
majority of patients with MDD will not achieve remission with first-line treatment and despite the 
availability of different treatment modalities, at least one-third of patients experience treatment-resistant 
depression (TRD). There continues to be a paucity of research focused on treatment options for patients 
with TRD thus treatment decisions are largely based on patient and clinician preference as opposed to 
evidence-based practice. Herein we propose a systematic review and network meta-analysis of available 
pharmacological and psychological augmentation treatments for TRD, to inform evidence-based 
management of TRD. 
 
Methods and analysis: We plan to conduct a search of electronic databases (MEDLINE and ISIWEB) 
of all dates from inception for randomized controlled trials of pharmacological and psychological 
augmentation interventions for adults with TRD. Articles for review will be included based upon 
consensus from two authors. Pharmaceutical companies will be contacted for access to any 
unpublished data. A network meta-analysis will compare the effectiveness pharmacological adjunctive 
agents for TRD using a pre-post analysis, assuming consistency and transitivity. The protocol has been 
registered with PROSPERO:  CRD42019132588 
 
 
Ethics and Dissemination: This project does not require research ethics board approval. The 
dissemination plan is to present findings at international scientific meetings and publishing results in a 
peer-reviewed academic journal.  
 
Strengths and Limitations of the study:  
• This will be the most comprehensive review of published and unpublished data of pharmacological 
and psychological augmentation treatments for TRD. 
• The results will provide the highest level of evidence to inform clinicians on the best choice of 
treatment from among the available pharmacological and psychological interventions for TRD. 
• The reporting of the protocol has been guided by PRISMA and has been registered with 
International Prospective Register of Systematic Reviews. 
• The study does not include brain stimulation interventions and trials of agents used as 
monotherapy.  
 
 
 
 
 
 
 
 
 
 
 Introduction 
As of 2017, the World Health Organization classifies major depressive disorder (MDD) as the leading 
cause of disability world wide.[1] Economic estimates report that the annual attributable financial loss due 
to MDD is $83 billion.[2] Though there are effective treatments for MDD, those who seek treatment are 
often faced with a relapsing and recurring course of illness. Based on community surveys, the finding that 
lifetime prevalence is two to three times that of 12-month prevalence suggests that between one-third 
and one-half of lifetime cases have recurrent episodes in a given year.[3] The STAR*D study, which was 
the largest naturalistic study on treatments for MDD to date, indicated that remission rates on the first 
treatment trial were approximately one third and subsequent remission rates decreased as the number 
of treatment trials increased.[4] The STAR*D findings indicate that at least a third of patients are likely to 
be experiencing treatment-resistant depression (TRD). Those suffering from TRD are left suffering from 
a significant decline in their social and occupational functioning and higher rates of all-cause mortality.[5] 
Persistent symptoms in TRD often translate into exponential increases in work loss and medical costs 
compared to more responsive forms of illness. 
In the clinical setting, very few patients are treatment naïve or are experiencing their first major depressive 
episode, yet the vast majority of research on treatment for MDD has focussed on single-episode 
depression. Very few studies have looked at the specific patient population that is treatment-resistant. 
When a patient presents as refractory to first line antidepressant (AD) medication, a crucial clinical 
question is whether to augment, make an AD switch or switch treatment modalities. A recent review 
outlined the current evidence-base and treatment modalities available for treatment-resistant depression 
(TRD).[6] Despite the summary of evidence, it does not provide guidance as to whether individuals should 
receive augmentation, discontinuation or switch to alternative treatment strategies. This decision 
remained largely dependent on patient and clinician preference.[6] Although there have been recent 
network meta-analyses published attempting to answer this clinical question, they have been limited by 
either setting a loose definition of TRD (i.e. one failed treatment only), restricting the search to a narrow 
range of publication dates, excluding unpublished data, excluding trials of psychological interventions, 
and excluding trials of novel treatment options such as anti-inflammatory agents.[7-9] Therefore we aim 
to address these limitations and herein present the protocol for a network meta-analysis of current 
available evidence of both psychological and pharmacological augmentation treatments for treatment-
resistant depression.  
Objective: 
To assess and compare the effectiveness of psychological and pharmacological augmentation 
treatments for treatment-resistant depression (TRD) using a network meta-analysis (NMA) approach. 
Since NMA combines evidence base on both direct and indirect comparison it maximises data included 
in analyses and provides relative estimates of effectiveness of all interventions considered. Specifically 
we aim to: 
1. Determine the effectiveness of all psychological and pharmacological adjunctive agents for TRD, in 
comparison to one another 
2. Determine the acceptability and tolerability of these treatments 
  
Methods and Analysis:  
 
The reporting of the protocol has been guided by the Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) statement.[10] The protocol has been registered with PROSPERO: 
CRD42019132588. 
 
 
 
Patient and Public Involvement 
 
Treatment resistant depression is a major public health concern and contributes to persistent suffering 
and frustration at an individual patient level.  Our findings will help address this concern to better serve 
the patients we see in practice. Since this is a secondary analysis, it was felt at this time, patient and 
public involvement was not required to inform the design of this particular study. As described above, 
we will widely disseminate our findings to reach the highest impact.  
 
Eligibility Criteria:  
 
Participants and setting 
 
We will include studies that recruited:  
- Participants of any gender.  
- Participants aged > 18. It may be that treatment efficacies differ for patients with late-life depression; as 
such, studies recruiting patients solely over age 65 will be excluded. Furthermore, we will conduct a 
sensitivity analysis to determine the effect of age on outcomes. 
- We will exclude studies that enrolled patients with comorbid neurologic disorders. 
- Any setting can be included and this data is extracted for potential network meta-regression.   
- Studies must have required participants to have treatment-resistant depression, defined as meeting all 
of the following criteria:  
a) Currently meets diagnostic criteria for major depressive disorder according to ICD 10 Code F32-3, 
DSM-IV 296  and DSM-5 296.[11-13] Trials with ICD 9 and DSM III/IIIR diagnoses approximating to these 
codes are also considered appropriate. 
b) Within the current depressive episode, have not sufficiently responded to at least two adequate trials 
of an evidenced based treatment for depression, as utilised in the most popular TRD definitions.[14-
16] Any studies that include non-response to within-class antidepressant switches (e.g. two SSRI’s, or 
two SNRI’s) as contributing to TRD will be included, due to evidence demonstrating that failure to respond 
after within-class antidepressant switch should contribute to the staging of TRD.[17] Similarly, we 
consider failure to respond to an adequate course of a psychological treatment to also contribute to TRD 
staging and thus this will be eligible for inclusion.[18] For instance, if patients have not responded to 
adequate trials of a SSRI and CBT, this will be eligible for inclusion in the present study. In line with 
commonly used TRD definitions, we will only consider treatment resistance within a current episode. 
 
We will exclude: 
- Studies of children or adolescents (<18 years of age), due to differing treatment mechanisms in young 
people, particularly with regard to antidepressants.  
- Studies where N < 10 participants randomised.[19] 
- Studies including patients with bipolar disorder and psychoses will be excluded (unless data are 
available for the subgroup of non-psychotic, unipolar participants), due to the well-documented 
differences in treatment efficacy for patients with these syndromes. However, multiple comorbidities are 
extremely common in TRD and therefore we will permit the inclusion of studies not excluding participants 
with most psychiatric and physical comorbidities. 
Interventions 
Permitted pharmacological treatments include those included in the Maudsley Treatment Inventory  
derived from the Maudsley Prescribing Guidelines and other standardised guidelines for depression 
treatment. We also include any treatment that has multiple meta-analyses supporting its use (e.g. 
minocycline, which is not included in the MTI).[20]  
 
For psychological agents, there has been far less standardisation and definition of appropriate 
antidepressant therapies. Permitted psychological treatments will comprise those recommended in the 
most recent NICE guidelines for depression (those only recommended for mild depression are not 
included) and comprise: computerised or face-to-face cognitive behavioural therapies (CBT), behavioural 
activation (BA), interpersonal therapy (IPT), manualised psychodynamic therapy (STPT), behavioural 
couples therapy, cognitive behavioural analysis system of psychotherapy (CBASP), or mindfulness-
based cognitive therapy (MBCT).  
 
Due to the variation between treatments in duration required for clinical effectiveness, trials will be 
considered adequate and therefore included if the article reports expectations of clinical efficacy. 
 
These are the criteria for both augmentation and initial treatments. While any evidence based initial 
treatment is permitted (pharmacological or psychological) it is anticipated that the majority of, if not all, 
studies will have recruited medicated TRD patients. 
Comparators 
Eligible comparator treatments include: Placebo, another pharmacological agent, another psychological 
intervention, waiting list, active control or treatment-as-usual (TAU).  
Outcomes 
 
We will only include studies that report depression-rating scales in each treatment arm.  
 
Study designs and publication types  
Randomised controlled trials (RCTs), cluster RCTs or the first phase of randomised cross-over 
trials. Trials must include randomisation to at least one suitable augmentation treatment (where patients 
are taking at least one continuing treatment prior to randomisation to further intervention). Eligibility of 
both initial and augmentation treatments is described below.  
 
Language and timeframe 
 
For any articles not available in English, maximum efforts will be made to translate text such that all 
studies can be included. The search will be created from all years up to the date of systematic search, 
December 21st 2018. We intend for the analysis and drafting of the manuscript to be reviewed and 
submitted to publication by September 1st ,2019.  
 
 
 
Information Source and Search Strategy: 
 
Electronic databases MEDLINE, www.clinicaltrials.gov, and ISI Web of Science will be searched along 
with citation lists from notable papers, available reviews and subsequently of included articles. The 
following search terms are applied:  
(depress* OR MDD OR major depress*) AND 
(resistan* OR refractor* OR non-respon* OR nonrespon* OR un-respon* OR unrespon* OR TRD OR fail* 
OR inadequate OR difficult OR intractable) AND 
(augment* OR adjunct* OR add-on OR combin* OR co-administ*) AND 
(randomi* OR RCT) AND 
(treatment OR intervention OR trial). 
 
For the network meta-analysis, the systematic search will be maximised by contacting pharmaceutical 
companies and additional authors in an attempt to collate data from unpublished studies 
Study Selection 
All studies generated from the systematic searches will be evaluated against the pre-defined inclusion 
criteria by two of the review authors independently. Any disparities will be addressed by reaching 
agreement via two additional review authors. We will use the GRADE approach to rank the quality of 
available evidence. 
 
Data Extraction  
This will be conducted by two review authors independently and will include quality assessment, 
description of participants, description of the intervention and control groups, psychometric data and 
outcomes. Disagreements will be resolved via further discussion with a third review author. 
 Assessment of risk of bias  
The methodological quality and specifically risk of bias, of included studies, will be addressed by 
employing the SIGN  (Scottish Intercollegiate Guidelines Network) tool in conjunction with the Cochrane 
risk of bias (RoB) tool. Two authors will extract this data independently, as above. The data extracted will 
relate to quality across nine domains: sequence generation, allocation concealment, blinding of outcome 
assessors, use of intention-to–treat (ITT) analysis, comparability of randomised groups at baseline, inter-
site differences in findings, the potential for selective outcome reporting and presence of for-profit bias 
(allegiance). Additional sources of bias that will be assessed will include novelty bias and sponsorship 
bias. A sensitivity analysis will assess the difference in statistical effects between studies with a high and 
low risk of bias. 
Outcome Measure(s) 
Primary outcome(s) 
The primary outcome will be treatment effectiveness using any validated assessment of illness severity, 
which is repeated from baseline to endpoint. Where multiple outcomes are reported, the primary outcome 
for inclusion in analyses will be selected in a hierarchical fashion: the most preferable scale will be a 
clinician-rated assessment of depression severity (HAM-D, MADRS, IDS or validated subscales of these), 
followed by a patient-rated measure (PHQ-9, IDS or BDI) or if not available, an assessment of global 
improvement (such as the CGI, LIFE chart measure, or GAS) or related symptoms (such as anxiety). 
Where multiple endpoints are reported, this review will consider the primary endpoint reported by each 
study. 
Secondary outcome(s) 
1. Response rate measured by the total number of patients who had a reduction of ≥50% of the total 
score on a standardised rating scale for depression. 
2. Remission rates as measured by a standardised rating scale for depression 
3. All-cause discontinuation will be used as a measure for the acceptability of treatments, because 
it encompasses efficacy and tolerability. 
Statistical Analysis 
Aggregate data (as opposed to individual patient-level) will likely need to be used for the present 
quantitative analyses. Descriptive statistics of study and participant characteristics will be examined and 
studies must be sufficiently homogeneous to be included in analyses. Pooled effect sizes (ES) will be 
calculated from continuous (standardised mean differences; Hedges’ g. Standard deviation (SD) will be 
input where possible, or imputed from standard errors (SE), confidence intervals (95% CI) or p-values.  
We will generate a network plot, consisting of all of the direct evidence, weighted by number of number 
of studies connecting the nodes. Relative effectiveness will be examined by calculating relative ES 
(probability of each treatment to be best). These probabilities are expressed by a Surface under the 
Cumulative Ranking curve (SUCRA) percentage, used to create the probability of the best treatment 
option, across all interventions.  
 
Depending on data availability, we may attempt to explore potential explanatory factors using sensitivity 
analysis / meta-regression. Examples of potentially important variables include: study quality, extent of 
treatment resistance, initial treatments, comorbidities, age, gender or ethnicity of sample, depression 
severity, duration of episode, duration of intervention, treatment setting. Novelty bias, sponsorship bias, 
definition or criteria used for TRD. These should be included as possible sources of inconsistency. 
 
Assumptions of the Network Meta-Analysis 
The comparator groups will be explored for homogeneity of clinical context. Where these are considered 
to not exhibit contextual diversity, the assumptions of transitivity and similarity will be compared by 
observation between direct and indirect comparisons. An intention-to-treat (ITT) approach will be taken 
to missing data. Heterogeneity of the network will be measured using I2, and τ2 within and across 
comparisons.  
 
Limitations: 
 
One of the main limitations of this review is that it only includes only of trials of augmentation treatments, 
thus excluding many of the ketamine investigations which have been trialled as a monotherapy. We also 
did not include trials of brain stimulation interventions, which are sometimes used with good effect for 
TRD. Since brain stimulation interventions are excluded, the findings may over-represent patients who 
are inappropriate for, or lack access to, brain stimulation treatments.  Our search strategy was limited to 
MEDLINE, Clinicaltrials.gov and ISI Web of Science although we expect adequate and efficient coverage 
with these databases. While interpreting the meta-analysis, we have to consider the heterogeneity of the 
dose/intensity and duration of the intervention, which is not always standardised across interventions.  
Network meta-analyses make both direct and indirect comparisons and we will aim to assess for 
inconsistencies of these two comparisons by using the node-splitting method in our statistical analysis.  
 
Ethics and Dissemination Plan:  
This project does not require research ethics board approval as it does not directly involve human or 
animal participants and is a review of available literature. We plan to present our findings at national and 
international scientific meetings. We also plan to publish our results in a reputable peer-reviewed 
academic journal.  
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